AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Bullish +72

AbbVie Stock Will Hit $300 on This Date

📈 CEO Robert A. Michael confirmed Q1 2026 results exceeded expectations with revenue accelerating to +12.4% YoY.

💊 Immunology segment generated $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%.

📉 Net income fell 45.96% YoY primarily due to a $744 million acquired-in-process R&D charge.

💸 Legacy franchises Humira and Imbruvica declined by 38.6% and 24.7% respectively, creating revenue headwinds.

🎯 Wall Street consensus target is $253.55, while the author's model projects a base case of $245.35.

🚀 Skyrizi crossed $5.01 billion in quarterly revenue and continues growing at over 30%.

🧠 Neuroscience franchise Qulipta showed strong momentum with a 53.6% increase in performance.

💰 Stock trades at a forward P/E of 17x, appearing cheap given operating margins above 32%.

📅 The author's 5-year bull case models the stock reaching $301 by June 2030.

⚠️ Primary risk identified is faster-than-expected erosion across the legacy oncology franchise.

Bullish Signals
  • Q1 2026 results exceeded expectations with revenue accelerating to +12.4% year-over-year despite market noise.
  • Immunology revenue hit $7.29 billion, driven by Skyrizi growth of 30.9% and Rinvoq growth of 23.3%.
  • Skyrizi crossed the $5.01 billion revenue mark last quarter while maintaining a growth rate above 30%.
  • Neuroscience franchise Qulipta demonstrated exceptional momentum with a 53.6% increase in performance.
  • The stock trades at a forward P/E of 17x against operating margins exceeding 32%, indicating potential undervaluation.
  • Management raised full-year guidance to $14.08-$14.28, signaling confidence in future earnings power.
  • Historical performance shows the stock returned 457.85% over 10 years and 131.55% over five years.
  • Analyst consensus remains overwhelmingly bullish with 8 Strong Buy and 16 Buy ratings out of 24 total.
Risk Factors
  • Net income fell 45.96% year-over-year due to a $744 million acquired-in-process R&D charge that clipped EPS by $0.41.
  • Structural decline in the Humira franchise caused revenue to fall 38.6% to $688 million.
  • Imbruvica revenue declined by 24.7%, adding pressure to overall top-line growth.
  • The market treats one-time R&D charges as recurring damage, potentially depressing valuation multiples.
  • Faster-than-expected erosion across the legacy oncology franchise could derail the path to $300.
  • Mega-cap dampening effects may cap the adjustment factor in valuation models despite sector momentum.
Full Analysis
AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by a 30.9% increase in Skyrizi and a 23.3% rise in Rinvoq. The article highlights a market disconnect where investors penalize the stock due to a one-time $744 million acquired-in-process R&D charge that reduced net income by 45.96%. This charge, along with structural declines in Humira revenue (down 38.6%) and Imbruvica (down 24.7%), has caused shares to trade at a discount despite strong operational fundamentals and low volatility. Analyst consensus targets the stock at $253.55, implying 14% upside, while the author's model projects a base case of $245.35 with an optimistic scenario reaching $301 by June 2030. Reaching $300 from current levels requires a 35.4% gain, achievable through continued growth in Skyrizi and Rinvoq, fading R&D charge noise, and sustained expansion in the neuroscience franchise. Key drivers for the bullish case include Skyrizi crossing $5.01 billion in revenue last quarter and Qulipta growing 53.6%. The stock currently trades at a forward P/E of 17x against earnings growth of over 12%, suggesting it is undervalued relative to its operating margins above 32%. However, risks include faster-than-expected erosion in the legacy oncology franchise and potential mega-cap dampening effects.